EPM looks at company relationships in the pharma sector to see which companies are teaming up for new developments and which companies are ‘taking a break’
Make-up: Bayer and Regeneron
Bayer and Regeneron Pharmaceuticals have recently been collaborating on a combination therapy to treat eye diseases and combat vision loss.
George Yancopoulos, chief scientific officer of Regeneron, said: “This new agreement reflects our shared commitment to being leaders in ophthalmology and to improving anatomical and visual outcomes for patients with retinal eye diseases."
Break-up: Sanofi and Merck
Sanofi Pasteur and MSD, known as Merck in the US, announced their intent to end their joint vaccines operations in Europe.
Upon concluding their joint venture, both companies plan to integrate their respective European vaccine businesses into their operations, independently manage their product portfolios and pursue their own distinct growth strategies in Europe.
Make-up: Consort and Precision Ocular
Consort and Precision Ocular have entered into a development and manufacturing agreement.
The collaboration will focus on the development, scale-up and industrialisation of Precision Ocular's novel drug products and drug delivery system, which is designed to access specific small spaces in the eye.
Make-up: Hovione and Vertex
Hovione is to host and operate a commercial-scale continuous manufacturing facility as part of an agreement with Vertex Pharmaceuticals.
The facility will be installed in Hovione’s New Jersey location, and Hovione said it expects the project to be complete by the end of 2017 to support the future manufacturing of Vertex’s approved medicines.
Are they, aren’t they? GSK and Qualcomm
GlaxoSmithKline (GSK) could be looking to at new ways to develop medical technologies with Qualcomm.
According to reports, GSK has hired lawyers to help negotiate the terms of a joint venture with the US chipmaker but earlier in January Qualcomm announced that it would be collaborating with Novartis.
